



## Zometa, zoledronic acid Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: \_\_\_\_\_ Date: \_\_\_\_\_  
Patient's ID: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_  
Physician's Name: \_\_\_\_\_  
Specialty: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Physician Office Telephone: \_\_\_\_\_ Physician Office Fax: \_\_\_\_\_

**Referring Provider Info:**  Same as Requesting Provider

Name: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Fax: \_\_\_\_\_ Phone: \_\_\_\_\_

**Rendering Provider Info:**  Same as Referring Provider  Same as Requesting Provider

Name: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Fax: \_\_\_\_\_ Phone: \_\_\_\_\_

*Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.*

**Required Demographic Information:**

Patient Weight: \_\_\_\_\_ kg

Patient Height: \_\_\_\_\_ cm

Please indicate the place of service for the requested drug:

- Ambulatory Surgical       Home       Off Campus Outpatient Hospital  
 On Campus Outpatient Hospital       Office

**Drug Information:**

Strength/Measure \_\_\_\_\_ Units  ml  Gm  mg  ea  Un

Directions(sig) \_\_\_\_\_ Route of administration \_\_\_\_\_

Dosing frequency \_\_\_\_\_

**Send completed form to: Priority Partners Fax: 1-866-212-4756**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Zometa, zoledronic acid 4mg SGM 2382-A – 04/2023.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076**

**Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com**

**Criteria Questions:**

1. What is the prescribed drug?  
 Zometa  
 zoledronic acid 4mg (generic)  
 Other \_\_\_\_\_
2. What is the diagnosis?  
 Hypercalcemia of malignancy  
 Multiple myeloma  
 Bone metastases from solid tumors  
 Prostate cancer  
 Breast cancer  
 Systemic mastocytosis  
 Langerhans cell histiocytosis with bone disease  
 Other \_\_\_\_\_
3. What is the ICD-10 code? \_\_\_\_\_
4. Is the request for continuation of therapy with the requested medication?  
 Yes  No *If No, skip to diagnosis section*
5. Is the patient diagnosed with hypercalcemia of malignancy?  Yes  No
6. Is the patient experiencing a benefit from therapy with the requested medication as evidenced by disease stability or disease improvement?  Yes  No *No further questions*

***Complete the following section based on the patient's diagnosis, if applicable.***

**Section A: Prostate Cancer**

7. Is requested medication prescribed for the treatment or prevention of osteoporosis during androgen-deprivation therapy (ADT) for a patient with a diagnosis of prostate cancer?  Yes  No

**Section B: Breast Cancer**

8. Is requested medication prescribed for a postmenopausal patient (natural or induced by ovarian suppression) who is receiving adjuvant therapy for the treatment of breast cancer?  Yes  No
9. Is the requested medication prescribed to maintain or improve bone mineral density and reduce the risk of fractures? *If Yes, no further questions*  Yes  No
10. Is the requested medication prescribed for risk reduction of distant metastasis in high-risk node negative or node positive tumors?  Yes  No

**Section C: Systemic Mastocytosis**

11. Is the requested medication prescribed for the treatment of osteopenia or osteoporosis in a patient with systemic mastocytosis?  Yes  No

**Section D: Multiple Myeloma, Bone Metastases Requested Medication Prescribed to Maintain or Improve Bone Mineral Density and Reduce the Risk of Fractures from Solid Tumors**

12. Is the requested medication being used to prevent skeletal-related events?  Yes  No

***I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.***

**X** \_\_\_\_\_

**Prescriber or Authorized Signature**

**Date (mm/dd/yy)**

**Send completed form to: Priority Partners Fax: 1-866-212-4756**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Zometa, zoledronic acid 4mg SGM 2382-A – 04/2023.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076**

**Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com**